Neurology
Amid the continued effects of the global Covid-19 pandemic, 2021 has been a year of remarkable activity in neurology therapeutics, encompassing treatments for the brain, spinal cord and nerves. New medicines for Alzheimer’s disease, migraine, and a host of rare conditions have been prominent in the medical literature and popular news and have been a major focus of industry educational and promotional activity.
Additionally, as there remain significant and in some cases profound unmet needs across the treatment categories under the neurology umbrella – almost none of the major conditions is amenable to disease modification or is curable – the pharmaceutical pipeline continues to abound with new drug candidates and new and more advanced mechanisms of action.
As this report will show, investigational treatments for rare, pediatric neurological diseases may be the most promising territory of drug development in this space and may hold wider promise in other neurological ailments.